Core Viewpoint - The controversy surrounding the efficacy and legitimacy of the drug ergothioneine, marketed by Kelun Pharmaceutical, has intensified following critical remarks from renowned biologist Rao Yi, who labeled it a "fake drug" and questioned the marketing tactics employed by the company's chairman, Liu Gexin [2][3]. Group 1: Company Actions and Market Reactions - Following Rao Yi's critical article, Kelun Pharmaceutical's stock dropped by 4.96% in a single day [3]. - The marketing campaign featuring Liu Gexin showcasing his physique to promote ergothioneine gained significant attention, leading to a temporary surge in stock prices prior to the backlash [3][5]. - Kelun Pharmaceutical's subsidiaries, including Chuaning Biological, are involved in the production and marketing of ergothioneine, which has been described as a "new dark horse in anti-aging" [5]. Group 2: Regulatory and Scientific Context - Ergothioneine has not yet received approval or registration from China's National Market Supervision Administration, which raises questions about its classification and marketing as a health product [5][6]. - The company claims that an application for ergothioneine as a new food ingredient was accepted by the National Health Commission in May 2024, but it remains under review [5]. - A health industry insider noted that while ergothioneine is considered a health food in some countries, it is classified as a regular food in China, necessitating compliance with advertising regulations [6].